A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
This study has been completed.
Information provided by (Responsible Party):
First received: December 12, 2012
Last updated: November 20, 2013
Last verified: November 2013
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine Headache patients who have received a minimum of 7 treatment cycles.
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Allergan:
Primary Outcome Measures:
- Number of Headache Days [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||November 2012|
|Study Completion Date:||August 2013|
|Primary Completion Date:||August 2013 (Final data collection date for primary outcome measure)|
Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
Previous treatment with onabotulinumtoxinA for Chronic Migraine.
Contacts and Locations